Trial
NCT07042295
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
Phase IISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Locally Recurrent Skin Squamous Cell Carcinoma
Intervention
Amivantamab and Recombinant Human Hyaluronidase
Why stopped
Other - safety run-in for initial cohort of participants
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-17